1Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004 [J]. Diagn Microbiol Infect Dis, 2005,53(4) :265-271.
6Clinical and Laboratory Standards Institute.2005.Performance standards for antimicrobial susceptibility testing;15 th informational supplement M100-S15.Wayne.Pennsylvania:CLSI,2005.100.
7Jones RN,Masterton R.Determining the value of antimicrobial surveillance programs.Diagn Microbiol Infect Dis,2001,41:171-175.
8Wang H,Chen M.Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China,1996 to 2002.Diagn Microbiol Infect Dis,2005,51:201-208.
9Kucisec-Tepes N.Pseudomonas aeruginosa--a significant hospital pathogen and resistance to carbapenem.Acta Med Croatica,2004,58:313-321.
6Thigpen M C, Whitney C G, Messonnier N E, et al. Bacterial meningitis in the United States, 1998-2007 [J]. N Engl J Med, 2011,364 (21) :2016- 2025.
7Somand D, Meurer W. Central nervous system infections [J]. Emerg Med Clin North Am, 2009,27(1) :89-100.
8Tunkel A R, Hartman B J, Kaplan S L, et al. Practice guidelines for the management of bacterial meningitis [ J ]. Clin Infect Dis, 2004,39(9) :1267-1284.
9Chang C J, Ye J J, Yang C C, et al. Influence of third-generation cephalosporin resistance on adult in-hospital mortality from post-neurosurgical bacterial meningitis[J]. J Microbiol Immunol Infect, 2010,43(4) :301-309.
